What is the treatment for tularemia caused by Francisella tularensis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Tularemia Caused by Francisella tularensis

Streptomycin is the drug of choice for treating tularemia, with gentamicin being an acceptable alternative when streptomycin is unavailable. For less severe forms, oral doxycycline or ciprofloxacin can be used 1.

First-Line Treatment Options

Severe Tularemia (Pneumonic, Typhoidal, or Critically Ill Patients)

  • Streptomycin: 1-2 g daily in divided doses for 7-14 days until the patient is afebrile for 5-7 days 2

    • Preferred agent with decades of clinical experience
    • Dosage: 30 mg/kg/day in 2 divided doses (maximum 2 g daily)
  • Gentamicin: When streptomycin is unavailable 1

    • Dosage: 3-5 mg/kg/day in 3 divided doses for adults
    • Dosage for children: 6 mg/kg/day in 3 divided doses
    • Adjust dosage according to renal function

Less Severe Forms (Ulceroglandular, Glandular)

  • Doxycycline: 100 mg twice daily for 14 days 1, 3
  • Ciprofloxacin: 750 mg twice daily for 14 days 1

Treatment Algorithm Based on Clinical Presentation

  1. Identify clinical form:

    • Ulceroglandular (cutaneous ulcer with regional lymphadenopathy)
    • Glandular (regional lymphadenopathy without ulcer)
    • Oculoglandular (conjunctivitis with preauricular lymphadenopathy)
    • Oropharyngeal (stomatitis/pharyngitis with cervical lymphadenopathy)
    • Intestinal (abdominal pain, vomiting, diarrhea)
    • Pneumonic (primary pleuropulmonary disease)
    • Typhoidal (febrile illness without localizing signs)
  2. Assess severity:

    • Severe: Pneumonic, typhoidal, or any form with systemic toxicity
    • Moderate to mild: Localized disease without systemic toxicity
  3. Select treatment:

    • Severe: Start with parenteral aminoglycoside (streptomycin or gentamicin)
    • Moderate/mild: Consider oral therapy with doxycycline or ciprofloxacin

Important Clinical Considerations

  • Treatment duration: Typically 7-14 days, continuing until patient is afebrile for 5-7 days 2
  • Monitoring: Watch for aminoglycoside toxicity (nephrotoxicity, ototoxicity)
  • Switching therapy: Consider transitioning from parenteral to oral therapy once clinical improvement occurs
  • Relapse risk: Higher with static drugs like tetracyclines or chloramphenicol, especially with shorter courses (< 10 days) 1

Special Populations

  • Children: Streptomycin 30 mg/kg/day in 2 divided doses; gentamicin 6 mg/kg/day in 3 divided doses 1
  • Adults > 60 years: Consider reduced aminoglycoside dosing due to increased risk of toxicity 2
  • Pregnancy: Aminoglycosides preferred over doxycycline or ciprofloxacin

Treatment Pitfalls and Caveats

  • F. tularensis is resistant to most β-lactam antibiotics, including ceftriaxone 1
  • Laboratory personnel should be notified when tularemia is suspected as the organism poses a significant laboratory hazard 1
  • Isolation requires specialized media containing cysteine or other sulfhydryl compounds 1
  • Mortality is relatively low (1.4%) with appropriate treatment, but can reach 60% in untreated pneumonic or typhoidal forms 4
  • Person-to-person transmission is minimal, so isolation is not typically required 1

Recent evidence suggests fluoroquinolones may be effective, but results have been mixed 1. The most recent guidelines still recommend aminoglycosides as first-line therapy for severe disease, with streptomycin being the preferred agent based on extensive clinical experience 1.

Human Medical Insights AI

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.